Breakdown | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
---|---|---|---|---|---|
Income Statement | |||||
Total Revenue | 11.64B | 10.53B | 9.56B | 8.60B | 6.35B |
Gross Profit | 6.74B | 6.52B | 5.95B | 5.25B | 4.04B |
EBITDA | 3.39B | 2.97B | 3.09B | 3.10B | 2.41B |
Net Income | 2.47B | 1.88B | 2.08B | 2.40B | 1.79B |
Balance Sheet | |||||
Total Assets | 24.99B | 22.52B | 22.37B | 21.06B | 16.98B |
Cash, Cash Equivalents and Short-Term Investments | 3.14B | 2.47B | 2.48B | 2.87B | 2.39B |
Total Debt | 4.44B | 3.40B | 4.48B | 3.65B | 2.39B |
Total Liabilities | 8.47B | 7.24B | 8.16B | 7.61B | 5.64B |
Stockholders Equity | 16.47B | 15.16B | 14.14B | 13.39B | 11.24B |
Cash Flow | |||||
Free Cash Flow | 1.28B | 1.93B | 245.79M | 1.49B | 1.31B |
Operating Cash Flow | 1.90B | 2.42B | 1.92B | 2.12B | 1.78B |
Investing Cash Flow | -2.00B | -515.75M | -2.58B | -2.05B | -2.05B |
Financing Cash Flow | 29.96M | -1.89B | 464.49M | -195.08M | 899.79M |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
---|---|---|---|---|---|---|---|
79 Outperform | 30.88B | 8.70 | 18.49% | 3.02% | 0.39% | 4.94% | |
74 Outperform | 35.97B | 13.63 | 0.00% | 3.45% | -2.20% | 11.99% | |
73 Outperform | HK$30.88B | 14.63 | 12.65% | 2.99% | 10.56% | -13.58% | |
72 Outperform | 23.06B | 6.34 | 4.96% | ― | -1.78% | 0.00% | |
71 Outperform | 36.15B | 20.48 | 9.93% | 2.01% | 11.78% | 19.06% | |
62 Neutral | 30.41B | 10.12 | 0.00% | 2.79% | 0.00% | 0.00% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
Grand Pharmaceutical Group Limited announced that its SIR-Spheres® Y-90 resin microsphere injection has received CE Mark approval in Europe for new indications in the treatment of liver cancer, expanding its application to include various types of unresectable liver tumors. This development, alongside recent FDA approval in the United States, enhances the company’s market positioning and demonstrates its strong clinical registration and commercial capabilities, supporting its global expansion strategy in nuclear medicine.
The most recent analyst rating on (HK:0512) stock is a Hold with a HK$9.00 price target. To see the full list of analyst forecasts on Grand Pharmaceutical Group Limited stock, see the HK:0512 Stock Forecast page.
Grand Pharmaceutical Group Limited has entered into a sales agreement with Yuanda Jiufu, a subsidiary of its controlling shareholder, China Grand Enterprises. This agreement involves the sale of raw materials for the production of amino acid and other pharmaceutical products. The transaction is categorized as a continuing connected transaction under Hong Kong’s Listing Rules, requiring reporting and announcement but exempting the need for a circular or shareholder approval. This move is expected to strengthen the company’s operational ties within its group, potentially enhancing its market position in the pharmaceutical sector.
The most recent analyst rating on (HK:0512) stock is a Hold with a HK$9.00 price target. To see the full list of analyst forecasts on Grand Pharmaceutical Group Limited stock, see the HK:0512 Stock Forecast page.
Grand Pharmaceutical Group Limited reported a slight increase in revenue for the first half of 2025, driven by its innovative and barrier products, which now account for over half of its total revenue. Despite facing challenges from price reductions due to centralized procurement, the company showed resilience through strategic execution and risk management. However, the profit attributable to the company’s owners decreased by 25% compared to the previous year, primarily due to reduced gains from Telix investment and increased marketing expenses. The company continues to invest heavily in research and development to support its growth strategy.
The most recent analyst rating on (HK:0512) stock is a Hold with a HK$9.00 price target. To see the full list of analyst forecasts on Grand Pharmaceutical Group Limited stock, see the HK:0512 Stock Forecast page.
Grand Pharmaceutical Group Limited has announced that its board of directors will hold a meeting on August 19, 2025, to review and approve the interim results for the first half of the year ending June 30, 2025. This meeting is significant as it will provide insights into the company’s financial performance and strategic direction, potentially impacting its market position and stakeholder interests.
Grand Pharmaceutical Group Limited announced a restructuring of its shareholding, with Outwit Investments Limited acquiring additional shares from East Ocean Capital, increasing its stake to 53.42% of the company’s total issued share capital. This internal restructuring, involving entities ultimately controlled by Beijing Huachuang, does not change the ultimate control of the company, and a waiver was obtained to avoid a general offer under the Hong Kong Code on Takeovers and Mergers.
Grand Pharmaceutical Group Limited has announced that its investigational radionuclide-drug conjugate, TLX591, for treating prostate cancer has received implied approval from China’s National Medical Products Administration to join an international Phase III clinical trial. This trial, involving over 500 patients across multiple countries, aims to evaluate the efficacy and safety of TLX591 in combination with standard care. The product, developed in collaboration with Telix Pharmaceuticals, offers a shorter treatment cycle and improved safety profile compared to existing therapies, potentially redefining the treatment standard for prostate-specific membrane antigen-positive metastatic castration-resistant prostate cancer.
Grand Pharmaceutical Group Limited has entered into a Business Collaboration Agreement with the Sirtex Group to jointly develop new radiopaque pharmaceutical products. This collaboration aims to leverage both companies’ expertise and resources, potentially enhancing their global presence and market opportunities by sharing R&D capabilities, resources, and technical knowledge.
Grand Pharmaceutical Group Limited announced the first commercial prescription of its nasal spray product, OC-01, for treating dry eye disease in Mainland China. This product, which is the first of its kind globally, offers a new treatment option for dry eye patients by increasing tear secretion through a nasal spray, potentially improving patient compliance compared to traditional eye drops. The company views ophthalmology as a strategic development area and aims to strengthen its market position with innovative products and a robust marketing network.
Grand Pharmaceutical Group Limited announced that its associate company, Sirtex Medical Pty Ltd, received early FDA approval for a new indication of its SIR-Spheres® Y-90 resin microsphere injection, now approved for treating unresectable hepatocellular carcinoma (HCC). This approval highlights the company’s strong clinical registration capabilities and supports its strategy to expand its nuclear medicine offerings globally, reinforcing its leadership in the industry. The product, which has been widely adopted and recognized for its effectiveness, is expected to enhance the company’s market position and provide significant growth opportunities.